Watson takes on drug-resistant cancer, drug safety
IBM continues to pursue healthcare applications for Watson as it attempts to further commercialize its hefty investment in the artificial intelligence technology.
The company has teamed up with the Broad Institute of MIT and Harvard on a five-year, $50 million research project to determine why some cancers are drug-resistant from the start and others are able to mutate to thwart treatment.
And it plans to collaborate with organizations such as Partners HealthCare hospitals in Massachusetts and possibly Memorial Sloan Kettering Cancer Center in New York to recruit patients to donate 10,000 tumor samples before and after treatment for data that can be parsed and analyzed by Watson, according to Boston Business Journal.
Read more: Fierce Healthcare